Patents Examined by Nicole Kinsey White
  • Patent number: 11655471
    Abstract: Disclosed are compositions and methods for increasing virus production. In particular, disclosed herein are cell or cell line comprises reduced expression of one or more cellular genes selected from the group comprising COQ9, FGF2, NAT9, NDUFA9, NEU2, PLA2G1B, PYCR1, RAD51AP1, STRADA, SVOPL, and/or ZFYVE9 for use in increasing viral production.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: May 23, 2023
    Assignee: University of Georgia Research Foundation, Inc.
    Inventor: Ralph A Tripp
  • Patent number: 11655461
    Abstract: Disclosed herein are methods and exemplary compositions associated with antigen purification, exemplary aspects of which may include harvesting viral and antigenic substances from source organisms; and a purification platform comprising chemical separation and size-difference separation for the removal of contaminants, debris and impurities from the viral and protein (e.g. antigenic, including influenza hemagglutinin antigens) substances, as well as their concentration and collection.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: May 23, 2023
    Assignee: KBIO HOLDINGS LIMITED
    Inventors: Steven D. Hume, Leigh Burden, Joshua Morton, Greg Pogue, Barry Bratcher, Hugh A. Haydon, Carrie A. Simpson, Nick Partain, John W. Shepherd, Kelsi Swope
  • Patent number: 11642422
    Abstract: The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in mammalian cells to provide gene therapy for pyruvate kinase deficiency.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: May 9, 2023
    Assignees: Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A, M.P., Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Consorcio Centro de Investigación Biomédica en Red, M.P.
    Inventors: Jose Carlos Segovia, Maria G. Gomez, Susana Navarro, Nestor Meza, Juan Antonio Bueren, Maria G. Bravo
  • Patent number: 11640851
    Abstract: A vaccine candidate is herein described comprised by statistically significant DNA fragments resulting in three types of compositions: 1) a composition of statistically significant DNA fragments, 2) a composition of RNA transcripts corresponding to the statistically significant DNA fragments, and 3) a computational reduction composition wherein the DNA fragments are fully or partially subtracted from a base organism, resulting in a synthetic organism which has a high statistical likelihood of problematic functions being partially or fully removed.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: May 2, 2023
    Inventor: Matthew Vernon Hanson
  • Patent number: 11633471
    Abstract: An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: April 25, 2023
    Assignees: UNM Rainforest Innovations, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Bryce Chackerian, Alan Remaley, Marcelo Amar, Alexandra Fowler
  • Patent number: 11635434
    Abstract: Methods for determination of risk, previous history and/or presence of a betaretrovirus infection in a subject are described herein. Said methods may comprise incubating a biological sample from the subject, the biological sample comprising immune effector-producing cells, with one or more betaretrovirus-specific epitopes, the betaretrovirus-specific epitopes comprising at least 7 contiguous amino acids according to any one of SEQ ID Nos. 1-36, and measuring the production of immune effectors by the immune effector-producing cells, wherein production of the immune effectors by the immune effector-producing cells determines risk and/or presence of betaretrovirus infection in the subject. Isolated peptides and kits for carrying out the methods are also described.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: April 25, 2023
    Inventors: Andrew L. Mason, Mandana Rahbari, Guangzhi Zhang
  • Patent number: 11624051
    Abstract: A composition or matrix comprising a bacteriophage and nanofibrillar cellulose or a derivative thereof in a wet or dry state is disclosed.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: April 11, 2023
    Assignee: UPM-KYMMENE CORPORATION
    Inventors: Mikael Skurnik, Saija Kiljunen, Sheetal Patpatia, Markus Nuopponen, Lauri Paasonen
  • Patent number: 11618780
    Abstract: Provided are compositions and methods for activating latent Human Immunodeficiency Virus (HIV). The compositions and methods may utilize a recombinant peptide that has a DNA binding zinc finger domain specific to the HIV long terminal repeat (LTR) sequence. The recombinant peptide may also have a transcription factor (e.g. a transcription activator) that is conjugated to the zinc finger domain. Also provided are methods of treating HIV in a subject in need of the treatment. The method may involve activation of latent HIV in cells of the subject and selectively removing such cells from the subject, providing complete and effective treatment of HIV.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: April 4, 2023
    Assignee: CITY OF HOPE
    Inventors: Kevin V. Morris, Marc S. Weinberg, Tristan Scott, Daniel Lazar
  • Patent number: 11613562
    Abstract: The multi-epitope SARS-COV2 Spike peptides are analyzed for their ability to form association or binding complex with HLA-DR1 and human TLR8 by using computer modeling and molecular docking experiments. These peptides are identified as candidates for vaccine development as well as antibody-based immunotherapy.
    Type: Grant
    Filed: June 13, 2021
    Date of Patent: March 28, 2023
    Inventor: Subhajit Dasgupta
  • Patent number: 11607449
    Abstract: A synthetic DNA vaccine against SARS-CoV-2 infection comprises a codon-optimized coding sequence for optimal mammalian expression of a pSARS2 spike glycoprotein (pSARS2-S). The signal peptide may be replaced with the signal peptide from the human IgG2 heavy chain. Systemic S1-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in mice at 2 weeks-post three injections with 100 ?g of the pSARS2-S vaccine via intramuscular (IM) needle injection. IM immunization induced Th1-skewed and long-lasting IgG response in BALB/c mice. Immunogenicity and induction of nAbs were enhanced with a needle-free delivery system, wherein two doses were sufficient to elicit significant levels of systemic S1-specific IgG antibodies and nAbs via IM or intradermal immunization.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: March 21, 2023
    Assignee: King Abdulaziz University
    Inventors: Anwar M. Hashem, Mohamed A. Alfaleh, Turki S. Abujamel, Sawsan S. Alamri, Abdullah Algaissi, Khalid A. Alluhaybi
  • Patent number: 11603542
    Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: March 14, 2023
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Qingmin Chen, Jinzhao Hou
  • Patent number: 11596680
    Abstract: A dry powder norovirus vaccine is provided, which comprises at least two norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infections.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: March 7, 2023
    Assignee: RESILIENCE GOVERNMENT SERVICES, INC.
    Inventors: Ron Cobb, Michael Springer, Yawei Ni
  • Patent number: 11596660
    Abstract: The present invention provides methods for treating an individual having bladder cancer comprising intravesically administering to the individual an oncolytic virus. Also provided are pharmaceutical compositions and kits for treating bladder cancer.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: March 7, 2023
    Assignee: CG ONCOLOGY, INC.
    Inventor: Arthur Kuan
  • Patent number: 11591617
    Abstract: The present invention relates to a method for transducing a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a poloxamer having a molecular weight of 12.8 kDa to about 15 kDa. Further, the invention relates to the use of a poloxamer as defined herein, optionally in combination with a polycationic substance as defined herein, for transducing a target cell with a retroviral vector and a kit comprising a retroviral vector, a poloxamer as defined herein and, optionally, instructions for use.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: February 28, 2023
    Inventors: Natasa Anastasov, Ines Höfig, Christian Thirion
  • Patent number: 11591633
    Abstract: Disclosed herein are methods and systems for rapid detection of microorganisms such as bacteria in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene encoding one subunit of an indicator protein. The specificity of the bacteriophage allows detection of a particular bacteria of interest and an indicator signal may be amplified to optimize assay sensitivity.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: February 28, 2023
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Stephen E. Erickson, Jose S. Gil, Wendy Hahn, Dwight L. Anderson
  • Patent number: 11583581
    Abstract: The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N1N2CGN3N4, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: February 21, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo, Ole Schmeltz Sogaard, Martin Tolstrup, Rasmus Offersen
  • Patent number: 11585812
    Abstract: There is provided an influenza virus detection chip and a method for detecting influenza virus therewith. An influenza virus detection chip including: a graphene oxide film; a first pad disposed on one side of the graphene oxide film in a first direction; and a first electrode and a second electrode, connected to both ends of the graphene oxide film in a second direction perpendicular to the first direction, wherein a first monoclonal antibody with a fluorescent label is included in the first pad, and a second monoclonal antibody is included in the graphene oxide film, and wherein the fluorescent label includes a C?C—C?C conjugated double bond.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: February 21, 2023
    Assignees: BEIJING BOE OPTOELECTRONICS TECHNOLOGY CO., LTD., BOE TECHNOLOGY GROUP CO., LTD.
    Inventors: Fengchun Pang, Chuncheng Che, Hailin Xue, Xibin Shao, Peizhi Cai
  • Patent number: 11578118
    Abstract: Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: February 14, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Justin J. Taylor, Howell F. Moffett
  • Patent number: 11576957
    Abstract: Provided herein are vaccine composition comprising an antigen conjugated to a capsid, wherein the capsid comprises wild type or native sequence. Provided herein are also vaccine composition comprising an antigen conjugated to a capsid, wherein said capsid comprises at least one mutation, such as a non-natural mutation. Such compositions are useful in the treatment and prevention of pathogenic infections, inflammatory diseases, and neurodegenerative disease, and cancer, among others.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: February 14, 2023
    Assignee: Board of Trustees of Michigan State University
    Inventors: Xuefei Huang, Suttipun Sungsuwan
  • Patent number: 11567079
    Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: January 31, 2023
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Christian Scholz, Peter Muench